888-969-2592
Kalkine 0
countryflagCA
Kalkine Login

RY 161.2 -1.8509% SHOP 138.97 -5.2176% TD 86.42 -0.9967% ENB 63.565 0.1024% BN 74.36 -4.0145% TRI 244.82 -0.9027% CNQ 43.695 -1.3211% CP 100.11 -2.4269% CNR 140.04 -1.8641% BMO 137.15 -1.267% BNS 68.325 -1.2645% CSU 4591.96 -1.5043% CM 80.13 -2.3043% MFC 44.03 -1.1672% ATD 69.99 -0.5683% NGT 68.92 -0.4478% TRP 68.76 -0.5064% SU 54.77 -0.9405% WCN 276.03 -0.4867% L 197.94 0.7226%

Neurocrine Biosciences Inc

Healthcare US NBIX

112.77USD
-1.23(1.08%)

Last update at 2025-03-28T18:57:00Z

Day Range

112.17113.92
LowHigh

52 Week Range

89.43148.37
LowHigh

Fundamentals

  • Previous Close 114.00
  • Market Cap14137.49M
  • Volume431954
  • P/E Ratio37.87
  • Dividend Yield-%
  • EBITDA492.90M
  • Revenue TTM1982.00M
  • Revenue Per Share TTM20.15
  • Gross Profit TTM 1001.70M
  • Diluted EPS TTM3.71

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 213.90M 101.40M 106.70M 46.50M 21.84M
Minority interest - - - - -
Net income 154.50M 89.60M 407.30M 37.00M 21.11M
Selling general administrative 752.70M 583.30M 433.30M 354.06M 248.93M
Selling and marketing expenses - - - - -
Gross profit 1465.50M 1119.20M 1035.80M 780.70M 446.35M
Reconciled depreciation 15.60M 10.90M 8.60M 7.45M 4.02M
Ebit 233.40M 196.90M 318.90M 219.15M 32.87M
Ebitda 249.00M 207.80M 327.50M 226.60M 36.90M
Depreciation and amortization 15.60M 10.90M 8.60M 7.45M 4.02M
Non operating income net other -28.00000M 24.70M -23.50000M 6.22M 15.48M
Operating income 249.00M 196.90M 318.90M 219.15M 36.90M
Other operating expenses 1239.70M 925.70M 718.40M 561.50M 414.35M
Interest expense 7.10M 25.80M 32.80M 32.00M 30.53M
Tax provision 59.40M 11.80M -300.60000M 9.53M 0.73M
Interest income - - - 25.74M 15.05M
Net interest income -7.10000M -25.80000M -32.80000M -31.96300M -30.53000M
Extraordinary items - - - - -
Non recurring - 105.30M 164.50M 154.27M -
Other items - - - - -
Income tax expense 59.40M 11.80M -300.60000M 9.50M 0.73M
Total revenue 1488.70M 1133.50M 1045.90M 788.10M 451.24M
Total operating expenses 1216.50M 911.40M 708.30M 554.10M 409.46M
Cost of revenue 23.20M 14.30M 10.10M 7.40M 4.89M
Total other income expense net -35.10000M -95.50000M -212.20000M -172.64800M 15.48M
Discontinued operations - - - - -
Net income from continuing ops 154.50M 89.60M 407.30M 37.01M 21.11M
Net income applicable to common shares 154.50M 89.60M 407.30M 37.01M 21.11M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3251.40M 2368.70M 2072.50M 1734.70M 1306.00M
Intangible assets 35.50M 37.20M - - 12.46M
Earning assets - - - - -
Other current assets 97.80M 464.20M 261.50M 215.20M 160.50M
Total liab 1019.40M 660.90M 698.50M 608.50M 669.10M
Total stockholder equity 2232.00M 1707.80M 1374.00M 1126.20M 636.90M
Deferred long term liab - - - - -
Other current liab 35.90M 292.00M 194.30M 147.10M 156.50M
Common stock 0.10M 0.10M 0.10M 0.10M 0.09M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.09M
Retained earnings -157.10000M -406.80000M -635.80000M -725.40000M -1132.70000M
Other liab - 29.70M 12.30M 9.70M 17.07M
Good will 5.80M - - - -
Other assets - 330.90M 319.50M 674.00M 59.07M
Cash 251.10M 262.90M 340.80M 801.00M 112.28M
Cash and equivalents - - - - -
Total current liabilities 654.80M 537.70M 245.80M 186.50M 565.30M
Current deferred revenue 339.90M - - - -46.21400M
Net debt 177.30M 169.40M 99.60M -388.70000M 383.22M
Short term debt 170.10M 169.40M 225.00M 94.00M 408.80M
Short long term debt 170.10M 169.40M - - 408.81M
Short long term debt total 428.40M 262.90M 440.40M 412.30M 495.50M
Other stockholder equity 2382.00M 2122.40M 2011.40M 1849.70M 1768.10M
Property plant equipment - 58.60M 58.60M 44.60M 41.91M
Total current assets 1607.00M 1453.50M 972.80M 1016.20M 831.00M
Long term investments 849.40M 401.50M 560.70M 227.10M 299.65M
Net tangible assets - 1670.60M 1374.00M 1126.20M 228.12M
Short term investments 780.50M 726.40M 370.50M 613.90M 558.25M
Net receivables 439.30M 350.00M 185.50M 157.10M 126.58M
Long term debt - - 335.10M 317.90M 408.81M
Inventory 38.30M 35.10M 30.50M 28.00M 17.29M
Accounts payable 108.90M 76.30M 51.50M 39.40M 46.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.00M -7.90000M -1.70000M 1.80M 1.41M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.10M 0.10M 0.09M
Preferred stock total equity - - - - -
Retained earnings total equity - -406.80000M -635.80000M -725.40000M -1132.70000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 49.60M 25.00M 4.40M 6.40M 3.20M
Deferred long term asset charges - - - - -
Non current assets total 1644.40M 915.20M 1099.70M 718.50M 475.00M
Capital lease obligations 258.30M 93.50M 105.30M 94.40M 86.76M
Long term debt total - - 335.10M 317.90M 408.81M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -110.20000M -102.20000M 15.00M -127.47800M -218.13700M
Change to liabilities 114.60M 56.80M 26.90M 53.95M 24.22M
Total cashflows from investing activities -177.10000M -130.20000M 4.10M -211.07300M -242.91500M
Net borrowings -279.00000M -0.10000M -186.90000M -186.90000M -186.90000M
Total cash from financing activities -234.30000M 27.40M -157.80000M 27.31M 29.53M
Change to operating activities -17.20000M -9.20000M -23.60000M 21.88M 2.66M
Net income 154.50M 89.60M 407.30M 37.01M 21.11M
Change in cash -73.30000M 153.70M 74.80M -31.70600M -112.02100M
Begin period cash flow 344.00M 190.30M 115.50M 147.19M 259.21M
End period cash flow 270.70M 344.00M 190.30M 115.48M 147.19M
Total cash from operating activities 339.40M 256.50M 228.50M 152.05M 101.36M
Issuance of capital stock - - - 27.31M 29.53M
Depreciation 15.60M 10.90M 8.60M 7.45M 4.02M
Other cashflows from investing activities -50.40000M -4.60000M -4.60000M -68.84700M 0.03M
Dividends paid - - - - -
Change to inventory -2.60000M -2.50000M -10.70000M -6.42400M -3.52400M
Change to account receivables -162.20000M -28.40000M -30.50000M -69.16900M -25.11300M
Sale purchase of stock 44.70M 27.50M 29.10M 27.31M 29.53M
Other cashflows from financing activities -177.10000M -130.20000M 4.10M -211.07300M -242.91500M
Change to netincome 266.30M 142.90M -188.60000M 76.02M 57.31M
Capital expenditures 16.50M 23.40M 10.90M 14.75M 24.81M
Change receivables -162.20000M -28.40000M -30.50000M -69.16900M -25.11300M
Cash flows other operating -48.00000M -30.10000M -5.90000M 34.87M 3.01M
Exchange rate changes - - - - -
Cash and cash equivalents changes -72.00000M 153.70M 74.80M -31.70600M -112.02100M
Change in working capital -67.40000M 16.70M -37.90000M 0.24M -1.75700M
Stock based compensation 173.10M 134.20M 100.00M 75.26M 58.07M
Other non cash items 44.50M 0.80M 61.20M 21.07M 19.23M
Free cash flow 322.90M 233.10M 217.60M 137.31M 76.55M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NBIX
Neurocrine Biosciences Inc		 -1.23 1.08% 112.77 37.87 26.11 7.18 6.07 6.86 36.15
ZTS
Zoetis Inc		 -1.585 0.96% 163.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.48 1.73% 28.23 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.157 0.83% 138.00 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.075 0.50% 15.06 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc

12780 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Kevin C. Gorman Ph.D. CEO & Director 1958
Mr. Matthew C. Abernethy Chief Financial Officer 1980
Dr. Jude Onyia Ph.D. Chief Scientific Officer 1964
Mr. Eric S. Benevich Chief Commercial Officer 1965
Dr. Eiry Wyn Roberts M.D. Chief Medical Officer 1964
Dr. Dimitri E. Grigoriadis Chief Research Officer 1958
Jane Sorensen Head of Investor Relations NA
Mr. Darin M. Lippoldt Chief Legal Officer & Corp. Sec. 1966
Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer 1973
Ms. Julie S. Cooke Chief HR Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.